Juan Carlos Galofre

Juan Carlos Galofre

Auto-generated profile, based on publicly available information

Juan Carlos Galofre

Department of Endocrinology, Clínica Universidad de Navarra, Pamplona, Spain

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2008 in Annals of Nutrition and Metabolism
Verified
Journal Article
Closed access
JGJ.C. Galofré
J.C. Galofré
PPP. Pujante
P. Pujante
CAC. Abreu
C. Abreu
SSS. Santos
S. Santos
Francisco Guillen-GrimaFrancisco Guillen-Grima
Francisco Guillen-Grima
JSJ. Salvador
J. Salvador
Background/Aims: Obesity has been associated with hypothyroidism and impaired insulin sensitivity. However, few studies have specifically addressed the association between insulin sensitivity and thyroid function. Our aim was to look for a relation between these 2 factors in a sample of obese males. Methods: One hundred and forty-four euthyroid male obese patients – mean age 42.6 years, mean body mass index (BMI) 41.8 – were enrolled in this cross-sectional study. The hospital study protocol at entrance included baseline serum thyroid-stimulating hormone (TSH), insulin and glucose concentrations. Data were studied using an age-adjusted simple and multivariate linear regression analysis with TSH as the dependent and insulin and BMI as the independent variables. Results: Mean TSH and insulin were 1.6 and 21.2 mU/l, respectively. It was found that their relationship follows a regression model: TSH = 1.725–0.019 (age) + 0.003 (insulin) + 0.017 (BMI). Further data showed a positive correlation between BMI and TSH (r = 0.22; p < 0.05), as well as between serum baseline insulin (>10 mU/l) and TSH concentration (r = 0.27; p < 0.05). This association was stronger in patients with higher insulin values (>21.2 mU/l; r = 0.40; p < 0.01). However, negative correlations between age and insulin (r = –0.14; not significant) and age and TSH (r = –0.35; p < 0.05) were observed. Conclusions: In obese males, insulin resistance is significantly related with impairment of thyroid function, and this situation seems to be attenuated with age.

1 December 2012 in International Journal of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
SPSilvia Santos Palacios
Silvia Santos Palacios
EPEider Pascual-Corrales
Eider Pascual-Corrales
JGJuan Carlos Galofre
Juan Carlos Galofre
Management of Subclinical Hyperthyroidism - International Journal of Endocrinology and Metabolism - - Kowsar

12 June 2018 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
SPSilvia Santos Palacios
Silvia Santos Palacios
MVMaría Llavero Valero
María Llavero Valero
ABAntonio Brugos‐Larumbe
Antonio Brugos‐Larumbe
JDJuan J. Díez
Juan J. Díez
FGFrancisco Guillén‐Grima
Francisco Guillén‐Grima
JGJuan C. Galofré
Juan C. Galofré

15 June 2024 in Journal of Endocrinological Investigation
Verified
Journal Article
Open access
PDF file
JGJ. C. Galofré
J. C. Galofré
JDJuan José Díez
Juan José Díez
RARoberto Attanasio
Roberto Attanasio
ENEndre V. Nagy
Endre V. Nagy
RNR. Negro
R. Negro
LHL. Hegedüs
L. Hegedüs
Purpose: The use of thyroid hormones (TH) to treat obesity is unsupported by evidence as reflected in international guidelines. We explored views about this practice, and associations with respondent characteristics among European thyroid specialists. Methods: Specialists from 28 countries were invited to a survey via professional organisations. The relevant question was whether “Thyroid hormones may be indicated in biochemically euthyroid patients with obesity resistant to lifestyle interventions”. Results: Of 17,232 invitations 5695 responses were received (33% valid response rate; 65% women; 90% endocrinologists). Of these, 290 (5.1%) stated that TH may be indicated as treatment for obesity in euthyroid patients. This view was commoner among non-endocrinologists (8.7% vs. 4.7%, p < 0.01), private practice (6.5% vs. 4.5%, p < 0.01), and varied geographically (Eastern Europe, 7.3%; Southern Europe, 4.8%; Western Europe, 2.7%; and Northern Europe, 2.5%). Respondents from Northern and Western Europe were less likely to use TH than those from Eastern Europe (p < 0.01). Gross national income (GNI) correlated inversely with this view (OR 0.97, CI: 0.96–0.97; p < 0.001). Having national guidelines on hypothyroidism correlated negatively with treating obesity with TH (OR 0.71, CI: 0.55–0.91). Conclusions: Despite the lack of evidence, and contrary to guidelines’ recommendations, about 5% of respondents stated that TH may be indicated as a treatment for obesity in euthyroid patients resistant to life-style interventions. This opinion was associated with (i) respondent characteristics: being non-endocrinologist, working in private practice, treating a small number of hypothyroid patients annually and (ii) national characteristics: prevalence of obesity, Eastern Europe, low GNI and lack of national hypothyroidism guidelines.

18 February 2024 in Thyroid®
Verified
Journal Article
Closed access
RARoberto Attanasio
Roberto Attanasio
MŽMiloš Žarković
Miloš Žarković
EPEnrico Papini
Enrico Papini
ENEndre V. Nagy
Endre V. Nagy
RNRoberto Negro
Roberto Negro
LHLaszlo Hegedus
Laszlo Hegedus
Background. Hypothyroidism is common, however, aspects of its treatment remain controversial. Our survey aimed at documenting treatment choices of European thyroid specialists and exploring how patients’ persistent symptoms, clinician demographics, and geo-economic factors relate to treatment choices. Methods. 17,247 thyroid specialists from 28 countries were invited to participate in an online questionnaire survey. The survey included respondent demographic data and treatment choices for hypothyroid patients with persistent symptoms. Geo-economic data for each country were included in the analyses. Results. The response rate was 32.9% (6,058 respondents out of 17,247 invitees). Levothyroxine (LT4) was the initial treatment preferred by the majority (98.3%). Persistent symptoms despite normal serum thyrotropin (TSH) while receiving LT4 treatment were reported to affect up to 10.0% of patients by 75.4% of respondents, while 28.4% reported an increasing such trend in the past five years. The principal explanations offered for patients’ persistent symptoms were psychosocial factors (77.1%), comorbidities (69.2%), and unrealistic patient expectations (61.0%). Combination treatment with LT4 + liothyronine (LT3) was chosen by 40.0% of respondents for patients who complained of persistent symptoms despite a normal TSH. This option was selected more frequently by female thyroid specialists, with high-volume practice, working in countries with high gross national income per capita. Conclusions. The perception of patients’ dissatisfaction reported by physicians seems lower than that described by hypothyroid patients in previous surveys. LT4+LT3 treatment is used frequently by thyroid specialists in Europe for persistent hypothyroid-like symptoms even if they generally attribute such symptoms to non-endocrine causes and despite the evidence of non-superiority of the combined over the LT4 therapy. Pressure by dissatisfied patients on their physicians for LT3-containing treatments is a likely explanation. The association of the therapeutic choices with the clinician demographic characteristics and geo-economic factors in Europe is a novel information and requires further investigation.

1 March 2014 in Endocrinología y Nutrición
Verified
Journal Article
Closed access
JGJuan Carlos Galofré
Juan Carlos Galofré
GRGarcilaso Riesco-Eizaguirre
Garcilaso Riesco-Eizaguirre
CECristina Alvarez Escola
Cristina Alvarez Escola